Supriya Lifescience Résultats passés
Passé contrôle des critères 4/6
Supriya Lifescience has been growing earnings at an average annual rate of 3.4%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 6.9% per year. Supriya Lifescience's return on equity is 17.4%, and it has net margins of 25.2%.
Informations clés
3.4%
Taux de croissance des bénéfices
1.7%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 17.5% |
| Taux de croissance des recettes | 6.9% |
| Rendement des fonds propres | 17.4% |
| Marge nette | 25.2% |
| Dernière mise à jour des bénéfices | 30 Sep 2024 |
Mises à jour récentes des performances passées
Recent updates
Supriya Lifescience (NSE:SUPRIYA) Has Announced That It Will Be Increasing Its Dividend To ₹0.80
Sep 08
We Think You Should Be Aware Of Some Concerning Factors In Supriya Lifescience's (NSE:SUPRIYA) Earnings
Jun 05Little Excitement Around Supriya Lifescience Limited's (NSE:SUPRIYA) Earnings
May 10Lacklustre Performance Is Driving Supriya Lifescience Limited's (NSE:SUPRIYA) Low P/E
Feb 09Supriya Lifescience's (NSE:SUPRIYA) Shareholders May Want To Dig Deeper Than Statutory Profit
May 28Market Cool On Supriya Lifescience Limited's (NSE:SUPRIYA) Earnings Pushing Shares 27% Lower
May 07Ventilation des recettes et des dépenses
Comment Supriya Lifescience gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Sep 24 | 6,250 | 1,575 | 931 | 0 |
| 30 Jun 24 | 5,990 | 1,352 | 723 | 0 |
| 31 Mar 24 | 5,704 | 1,191 | 862 | 0 |
| 31 Dec 23 | 5,545 | 1,204 | 832 | 0 |
| 30 Sep 23 | 5,195 | 1,001 | 803 | 0 |
| 30 Jun 23 | 4,916 | 931 | 583 | 0 |
| 31 Mar 23 | 4,609 | 899 | 730 | 0 |
| 31 Dec 22 | 5,069 | 978 | 696 | 0 |
| 30 Sep 22 | 5,188 | 1,280 | 734 | 0 |
| 30 Jun 22 | 5,545 | 1,693 | 534 | 0 |
| 31 Mar 22 | 5,300 | 1,518 | 656 | 0 |
| 31 Dec 21 | 4,754 | 1,543 | 629 | 0 |
| 31 Mar 21 | 3,912 | 1,236 | 501 | 0 |
| 31 Mar 20 | 3,200 | 734 | 345 | 0 |
| 31 Mar 19 | 2,818 | 394 | 261 | 0 |
| 31 Mar 18 | 2,168 | 87 | 230 | 0 |
Des revenus de qualité: SUPRIYA has a high level of non-cash earnings.
Augmentation de la marge bénéficiaire: SUPRIYA's current net profit margins (25.2%) are higher than last year (19.3%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: SUPRIYA's earnings have grown by 3.4% per year over the past 5 years.
Accélération de la croissance: SUPRIYA's earnings growth over the past year (57.3%) exceeds its 5-year average (3.4% per year).
Bénéfices par rapport au secteur d'activité: SUPRIYA earnings growth over the past year (57.3%) exceeded the Pharmaceuticals industry 19.1%.
Rendement des fonds propres
ROE élevé: SUPRIYA's Return on Equity (17.4%) is considered low.